The effect of Ca-Dobesilate over renal scar formation in an experimental pyelonephritis model
Öz
Purpose: This study was conducted to evaluate the effects of the drug: Ca-Dobesilate (CaD) which has been in common use in venous insufficiency treatment; on renal scarring and expressions of transforming growth factor beta1 (TGFb1), basic fibroblast growth factor (bFGF) and hepatocyte growth factor-beta (HGF-beta) in a rat pyelonephritis model.
Materialw and Methods: Eight pyelonephritis groups, each constituting of 7 rats were developed as no treatment - ciprofloxacin – ciprofloxacin and CaD administered groups; following injecting E Coli (ATCC 25922) into kidney. No treatment given rat groups were sacrificed following 24h, 72 h, 14d and 28d from bacterial seeding respectively. Rats from treatment groups were sacrificed after 14d and 28d accordingly. Diagnoses of pyelonephritis and fibrosis, TGFb, bFGF and HGF-beta were scored semiquantitatively by immunohistochemical staining.
Results: The extent of pyelonephritis and fibrosis was lower in rats treated with ciprofloxacin and CaD compared to sole ciprofloxacin and no treatment administered counterparts among groups terminated after 2wks following bacterial inoculation. However, CaD effect on pyelonephritis and fibrosis scores did not persist after treatment was discontinued.
Conclusion: CaD might alleviate pyelonephritis and scarring, depending on dosage and treatment period and further studies are needed to determine optimum treatment dose and duration.
Anahtar Kelimeler
ca-dobesilate, kidney fibrosis, pyelonephritis model, pyelonephritis,
Destekleyen Kurum
çukurova üniversitesi tıp fakültesi
Proje Numarası
This study was approved by the Animal Ethics Committee of Cukurova University Affliated to Cukurova University Medical Sciences Experimental Animals Research Center Adana with the verification number “B.30.2.CKO.0.5L.00.00-128”.
Teşekkür
Cukurova University Medical Sciences Experimental Animals Research Center Adana
Kaynakça
- References 1. Eddy AA. Molecular basis of renal fibrosis. Pediatr Nephrol 2000;15:290-301.
- 2. Eddy AA. Overview of the cellular and molecular basis kidney fibrosis. Kidney International Suplements 2014:4:2-8.
- 3. Genovese F, Manresa AA, Leeming DJ, Karsdal MA, Boor P. The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis? Fibrogenesis Tissue Repair 2014:7:4.
- 4. Guan X, Nie L, He T, Yang K, Xiao T, Wang S, Huang Y, Zhang J, Wang J, Sharma K, Liu Y, Zhao J. Klotho supresses renal tubulo-interstitial fibrosis by controlling basic fibroblast growth factor-2 signalling. J Pathol 2014;234: 4;560–572.
- 5. Strutz F. The role of FGF-2 in renal fibrosis. Frontiers in Bioscience 2009;Suppl 1;125-131.
- 6. Youhua Liu. Renal fibrosis: New insights into the pathogenesis and therapeutics. Kidney Int 2006;69(2):213–217.
- 7. Xu J, Yu T-T, Zhang K, Li M, Shi H-J, Meng X-J, Zhu L-S, Zhu K.. HGF alleviates renal interstitial fibrosis via inhibiting the TGF-β1/SMAD pathway. Eur Rev Med Pharmacol Sci 2018;22 (22):7621-7627.
- 8. Zhou Y, Qi C, Li S, Shao X, Mou S, Ni Z. Diabetic nephropathy can be treated withCalcium Dobesilate by alleviating the chronic inflammatory state and improving endothelial cell function. Cell Physiol Biochem 2018;51:1119-1133.
- 9. Liu X, Liu X. Effect of calcium dobesilate on nephropathy in type 2 diabetic rats. Huazhong Univ Sci Technolog Med Sci 2005;25:36-38.
- 10. Cuaves P. Treatment of basal cell carcinoma with dobesilate. J Am Acad Dermatol 2005;33:526-527.
